Opendata, web and dolomites

ONCO-VAX SIGNED

A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCO-VAX project word cloud

Explore the words cloud of the ONCO-VAX project. It provides you a very rough idea of what is the project "ONCO-VAX" about.

employ    strategy    stimulating    lysis    hepatocellular    imposes    onco    subset    enhanced    financially    restricts    combat    oncology    successful    eradicating    spread    immunity    innovative    combination    solid    paradigm    vax    nevertheless    potentially    intratumoral    patient    cell    medical    limited    cancer    treat    broad    malignancy    layer    platform    elegant    multifaceted    microenvironment    reaching    scheme    stimulatory    heavy    capacity    metastatic    backbone    immune    ovs    therapeutic    mass    direct    synergistic    disease    therapy    burden    treating    societal    antiviral    epidemiologically    local    additional    multimodal    liver    ov    directed    systemic    viruses    chimeric    dramatic    gene    utilized    dendritic    combined    despite    shift    inherently    intensive    tumors    suppressive    innate    spreading    replication    basis    monotherapeutics    patients    optimized    cutting    immuno    virus    hcc    tumor    edge    health    vaccine    carcinoma    life    immunotherapy    initiate    express    transforming    decades    oncolytic    worldwide    antitumor    disappointing    mechanism   

Project "ONCO-VAX" data sheet

The following table provides information about the project.

Coordinator
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN 

Organization address
address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675
website: http://www.med.tu.muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙988 €
 EC max contribution 1˙499˙988 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) coordinator 1˙499˙988.00

Map

 Project objective

Despite many decades of intensive research, cancer remains a major worldwide health concern and imposes a heavy societal burden, both epidemiologically and financially. Cancer immunotherapy is rapidly transforming the face of medical oncology as an exciting paradigm shift in treating cancer by exploiting the immune system of the patient as the basis for the therapy. Although dramatic results have been achieved in a subset of patients, the responses in most solid tumors have been disappointing. Hepatocellular carcinoma (HCC) represents a particularly challenging malignancy to treat, due to the inherently immune-suppressive microenvironment in the liver. Oncolytic viruses (OVs) offer an elegant multimodal approach to combat HCC through their ability to cause direct tumor cell lysis, while stimulating immune responses directed against the tumor. Nevertheless, the potential of OVs as monotherapeutics is limited by the innate antiviral immune response, which rapidly restricts virus replication and spread within the tumor mass. Therefore, a successful therapeutic strategy should employ a combination scheme involving a mechanism to improve the intratumoral dissemination of the OV, while exploiting the immune-stimulatory capacity of the virus, in order to achieve far-reaching synergistic responses that can target metastatic disease. The ONCO-VAX approach aims to accomplish just that. A novel chimeric oncolytic virus backbone with an enhanced cell-cell spreading capacity, will be utilized as a platform to express an optimized gene for eradicating the local immune-suppressive microenvironment in the tumor. As an additional layer of therapy, the virus will be combined with a cutting edge dendritic cell vaccine approach to initiate a broad antitumor response for systemic and potentially life-long immunity against the cancer. This multifaceted approach represents an innovative and crucial step forward in the rapidly evolving field of cancer immuno-oncology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCO-VAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCO-VAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

GTBB (2019)

General theory for Big Bayes

Read More  

MitoGuide (2019)

Integration and adaptation of impaired mitochondrial fitness in orchestrating T cell dysfunction in the tumor microenvironment

Read More